RARE shares plunge after Angelman late-stage trial failure, downgraded
Ultragenyx Pharmaceutical’s experimental Angelman syndrome therapy failed a key late-stage trial, triggering analyst downgrades and fresh concerns. RARE shares were down 45% in pre-market trading.
Ultragenyx Pharmaceutical (RARE) was in focus on Thursday after its experimental Angelman syndrome therapy failed a key late-stage trial, triggering analyst downgrades and renewed concern over the company’s growth outlook. RARE shares were down 45% in pre-market trading and are on track for their biggest single-day percentage decline on record.